linjc16/ctgov huggingface dataset:
Transcranial Low Intensity Focused Ultrasound Neuromodulation as a Probe to Study Human Emotion and Cognitive Function

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the low-intensity focused ultrasound pulsation (LIFUP) neuromodulation on emotion processing in healthy individuals, and to assess the overall safety of the LIFUP to stimulate or inhibit brain activity in healthy volunteers.

Official Title
-----------------
Transcranial Low Intensity Focused Ultrasound Neuromodulation as a Probe to Study Human Emotion and Cognitive Function

Conditions
-----------------
Depressive Disorder, Major

Intervention / Treatment
-----------------
* Device: LIFUP sonication to the amygdala


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be right-handed Must be illicit drug-free at the time of scanning as appropriate (verified by negative urine drug screen) Must be healthy (without medical, neurological, psychiatric illness) Must be psychotropic medication free (≥ 14 days) Exclusion Criteria: Must not be a smoker Females must not be pregnant or nursing Must not suffer from claustrophobia Must not meet exclusion criteria for MRI scanning (i.e., non-fixed magnetizable objects) Must not have ongoing, chronic, or relapsing/remitting medical, psychiatric,or neurological illness as determined by a combination of history, medical record, and/or examination.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LIFUP sonication to the amygdala<br> | Device: LIFUP sonication to the amygdala<br>* LIFUP sonication to amygdala will be performed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in amygdala activity indicated by functional magnetic resonance imaging (fMRI) scan blood oxygen-level-dependent (BOLD) signal |  | baseline, 5 mins post-LIFUP sonication | 
| Changes in brain resting state functional network as indicated by fMRI scan connectivity measures |  | baseline, 10-20 mins post-LIFUP sonication | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in performance on Reward Task |  | baseline, 1-hour post-LIFUP sonication | 
| Tolerability of LIFUP sonication as assessed number of adverse events |  | baseline, immediately after LIFUP sonication | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, mental illness
Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Official Title
-----------------
Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma

Conditions
-----------------
Pancreatic Tubular Adenocarcinoma

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ECOG performance status 0-2 at the time of inclusion Following R0 or R1 pancreatic tubular adenocarcinoma resection Exclusion Criteria: Pregnancy Serious comorbidity

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pancreatic tubular adenocarcinoma<br>Patients with pancreatic tubular adenocarcinoma | Other: Observation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreatic tubular adenocarcinoma, gemcitabine, gene expression, immunological status, serological status, pancreatic tubular adenocarcinoma adjuvant setting
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

Study Overview
=================
Brief Summary
-----------------
This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

Detailed Description
-----------------
The emergence of multidrug resistant is a wordwide problem. B lactam resistant increase. The antibiotic prescription impact this problem. B lactam antibiotic is prescribed everyday in intensive care unit. The switch of antibiotic is common. Antibiotic classes inclue a lot of rank with different spectum that impact the occurrence of resistant.

Official Title
-----------------
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

Conditions
-----------------
Resistant Infection, Antibiotic Resistant Infection, Beta Lactam Resistant Bacterial Infection, Bacterial Resistance

Intervention / Treatment
-----------------
* Procedure: number of Beta lactam class prescription for the same infection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patient hospitalized more than 48 hours in intensive care unit in Besançon between january 2016 and december 2017 Exclusion Criteria: patient under guardianship patient allergic to Beta lactam colonization with mutidrug resistant the first week of hospitalization in intensive care unit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| case<br>Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017. | Procedure: number of Beta lactam class prescription for the same infection<br>* Each number of Beta lactam prescription without interruption are compared<br>|
| control<br>Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017. | Procedure: number of Beta lactam class prescription for the same infection<br>* Each number of Beta lactam prescription without interruption are compared<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of Beta lactam class prescription |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antibiotic resistant, multidrug resistant, Beta lactam
Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol

Study Overview
=================
Brief Summary
-----------------
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Today more than 90% of children and 75% of adults (18-45 years) survive ALL. The enzyme Asparaginase (Asp) is an indispensable part of the multiagent treatment of ALL. Treatment related severe acute toxicities are common. Especially in teenagers and adults, thromboembolism is one of the most common acute toxicities and may result in post thrombotic syndrome (PTS) or pulmonary hypertension. The knowledge about these late effects is limited, including for ALL patients.

Official Title
-----------------
Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol

Conditions
-----------------
Acute Lymphoblastic Leukemia, Post Thrombotic Syndrome

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treated on the ALL2008 protocol for ALL. Had a DVT on treatment. Exclusion Criteria: Death

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|Examination of patients with previous DVT|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with post thrombotic syndrome |  | 01112020-01022023 |
Intravenous Artesunate and Malaria

Study Overview
=================
Brief Summary
-----------------
Intravenous artesunate is egual to quinine in the treatment of severe malaria

Detailed Description
-----------------
Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of fever clearance time and parasite clearance time

Official Title
-----------------
Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan

Conditions
-----------------
Malaria

Intervention / Treatment
-----------------
* Drug: artesunate
* Drug: Quinine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe P.falciparum malaria- Exclusion Criteria: mixed infection Pregnant women -

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: artesunate<br>intravenous artesunate 80 mg/kg initially then after 8 hours then daily | Drug: artesunate<br>* intravenous artesunate 80 mg/kg initially then after 8 hours then daily<br>Drug: Quinine<br>* quinine infusion 80 mg/kg every 8 hours till the patient can take orally<br>|
| Active Comparator: quinine<br>quinine infusion 80 mg/kg every 8 hours | Drug: artesunate<br>* intravenous artesunate 80 mg/kg initially then after 8 hours then daily<br>Drug: Quinine<br>* quinine infusion 80 mg/kg every 8 hours till the patient can take orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clearance of the parasite and fever | To compare the parasite clearance time and fever clearance time between the two groups | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
severe, Falciaparum, Malaria
Study to Determine How Exercise and Calcium Affect Pubertal Bone

Study Overview
=================
Brief Summary
-----------------
To determine if increasing the amount of calcium that girls eat or the degree of exercise in which they participate will increase their bone strength.

Official Title
-----------------
Effect of Exercise and Calcium Foods on Pubertal Bone Gain

Conditions
-----------------
Bone Health

Intervention / Treatment
-----------------
* Behavioral: exercise
* Behavioral: exercise and calcium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 9-10 years of age Premenarcheal Female Exclusion Criteria: corticosteroid or anticonvulsant therapy lactose intolerance or milk allergy family history of hypercholesterolemia mental or physical handicaps chronic disease body mass index ³ 85th percentile for age and gender baseline calcium intake of > 1100 mg/day participation in team sports > 3 times per week

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br>exercise class 3x's/week | Behavioral: exercise<br>* exercise class 3x's/week<br>|
| Experimental: exercise and calcium intake<br>exercise class 3x's/week and 1500mg calcium/day | Behavioral: exercise and calcium<br>* exercise class 3x's/week and 1500mg calcium intake<br>|
| No Intervention: usual exercise and calcium<br>usual exercise and calcium intake | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bone health, bone density, bone mass
Anaesthesia and mHealth

Study Overview
=================
Brief Summary
-----------------
This survey aims to better define the wishes/needs of the Belgian Anaesthesiologists within the field of mobile technology, namely, what would help improve the daily anaesthesia practice.

Detailed Description
-----------------
This study consists of a simple online survey that takes approximately 3 minutes to complete. The study aims to assess the confidence of the belgian anaesthesiologists on smartphone applications and dedicated smartphone peripherals, on how these can be used in daily practice, as well as what their wishes for further developments are.

Official Title
-----------------
Anaesthesia and mHealth

Conditions
-----------------
Anesthesia, Cell Phone, Mobile Applications

Intervention / Treatment
-----------------
* Other: questionary


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active diploma-holding Anesthesiologist working in Belgium Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionary|The intervention consists of a digitally distributed questionary.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire about the Confidence (scale 0-5) on Mobile Apps and Peripheral Devices in Anesthesiology | Confidence of Anesthesiologist on the use of Mobile Apps and Peripheral Devices in improving anesthesia care. | One single time-point assessment (time of filling in the questionnaire) during 3 months (time during which the filling-in of the questionnaire is possible) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anesthesia, Cell Phone, Mobile Applications
A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

Study Overview
=================
Brief Summary
-----------------
Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.

Official Title
-----------------
A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone

Conditions
-----------------
Lung Disease, Pulmonary Fibrosis

Intervention / Treatment
-----------------
* Drug: interferon-gamma 1b
* Drug: azathioprine


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: interferon-gamma 1b|This study was terminated prior to enrollment.|
|Drug: azathioprine|This study was terminated prior to enrollment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This study was terminated prior to enrollment. |  | This study was terminated prior to enrollment. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
idiopathic pulmonary fibrosis
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Study Overview
=================
Brief Summary
-----------------
To test the effectiveness of MNTX in advanced illness subjects.

Detailed Description
-----------------
To determine the efficacy of MNTX compared to placebo to induce laxation in patients receiving opioids.

Official Title
-----------------
A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness

Conditions
-----------------
Advanced Illness Patients With Opioid Induced Constipation

Intervention / Treatment
-----------------
* Drug: SC Methylnaltrexone
* Drug: SC Placebo
* Drug: SC Methylnaltrexone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced medical illness with a life expectancy of 1 to 6 months No clinically significant laxation within 48 hours prior to the first dose of study drug On stable opioid and laxative regimen for a least 3 days prior to treatment Age greater than 18years Females of child-bearing age must have a negative pregnancy test. Exclusion Criteria: Females who are pregnant or nursing. Previous treatment with MNTX or prior treatment with naltrexone or naloxone for treatment of OIC Any disease process suggestive of gastrointestinal obstruction Fecal ostomy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: SC Methylnaltrexone<br>* Dose 1<br>|
| Placebo Comparator: Arm 3<br> | Drug: SC Placebo<br> <br> |
| Experimental: Arm 2<br> | Drug: SC Methylnaltrexone<br>* Dose 2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of SC MNTX compared with placebo in inducing laxation | The primary objective is to determine the efficacy of SC MNTX administered as a single dose, dose 1 and dose 2 compared with placebo in inducing laxation in 4 hours in patients with advanced medical illness and OIC who are poorly responsive to laxatives. | 29 days |
Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Prospective, Interventional, Non-Randomized, Open Label, Single Group Assignment, Single Center.

Official Title
-----------------
Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

Conditions
-----------------
Osteoarthritis Knee

Intervention / Treatment
-----------------
* Device: Ozone gas
* Drug: Steroid injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 55 to 79 years of age Symptomatic Knee osteoarthritis VAS pain intensity is at least 40 mm on a 100 mm scale Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits. Exclusion Criteria: Any known tumor of the ipsilateral knee. Any known infection of the treated knee. Osteoarthritis of the operated knee Kelgren Lawrence < grade 2. Chemotherapy treatment in the past 12 months. Patients who are sensitive to ozone. Pregnant women, or breastfeeding women. Evidence of any significant systemic disease (such as but not limited to HIV infection, hepatitis infection or HTLV infection), known coagulopathies, that might compromise the Subject's welfare. Substance abuse or alcohol abuse. Participation in other clinical trials in parallel to this study.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: A sequential series of patients receiving steroid injections was compared to a sequential series of patients receiving ozone injections
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OZONE<br>injection of ozone gas | Device: Ozone gas<br>* Injection of ozone gas intra articularly<br>|
| Active Comparator: control<br>injeciton of steroids intra articularly | Drug: Steroid injection<br>* Injection of steroids (diprospan) intra articularly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in VAS Pain intensity | The outcome measure will be measured according to patient response to the question: during the last week what was your average pain intensity. The response will be measured in millimeters as marked on a 10 cm long line. No pain equals 0 mm and maximal possible pain equals 100mm | 6 months |